Publications by authors named "Eric Zuk"

Claim this Profile
C
Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States.
Matthew Matasar, Javier Sanchez Alvarez, Hélène Parisé, Eric Zuk, Danilo Di Maio

J Med Econ· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis